Takeda Pharmaceuticals - Initiating Coverage - In Pursuit of Growth Drivers
We initiate coverage on Takeda Pharmaceutical with a neutral rating and a DCF based target price of ÂĄ 5,200. We expect the Entyvio, Ninlaro and...
289 Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
594 Views
Trintellix (Vortioxetine) – Selective Serotonin Reuptake Inhibitor (SSRI) And Partial Agonist
While sales of Takeda's long listed products (~ 20% of sales in FY15) continue to decline, expectations remain bleak for its late stage pipeline.We...
257 Views
Ninlaro (Ixazomib) - Oral Proteasome Inhibitor
Ninlaro (ixazomib, formerly MLN9708, Takeda) is the first and the only oral proteasome inhibitor, approved by USFDA (Nov’15) (three months ahead...
281 Views
American Society of Hematology- (ASH) Annual Conference (2016) Review
We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment...
461 Views